ReP USP - Resultado da busca

Filtros : "Financiamento FAPESP" "GUIDO, RAFAEL VICTÓRIO CARVALHO" "Financiamento NHMRC" Limpar

Filtros

Artigo de periodico
A potent and selective reaction hijacking inhibitor of Plasmodium falciparum tyrosine tRNA synthetase exhibits single dose oral efficacy in vivo (2024)
Xie, Stanley C. ; Guido, Rafael Victorio Carvalho
Fonte: PLOS Pathogens. Unidade: IFSC
Assuntos: PLASMODIUM FALCIPARUM, ANTIMALÁRICOS, FÁRMACOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
XIE, Stanley C. e GUIDO, Rafael Victorio Carvalho. A potent and selective reaction hijacking inhibitor of Plasmodium falciparum tyrosine tRNA synthetase exhibits single dose oral efficacy in vivo. PLOS Pathogens, v. 20, n. 12, p. e1012429-1-e1012429-28 + supporting information, 2024Tradução . . Disponível em: https://doi.org/10.1371/journal.ppat.1012429. Acesso em: 08 out. 2025.
APA
Xie, S. C., & Guido, R. V. C. (2024). A potent and selective reaction hijacking inhibitor of Plasmodium falciparum tyrosine tRNA synthetase exhibits single dose oral efficacy in vivo. PLOS Pathogens, 20( 12), e1012429-1-e1012429-28 + supporting information. doi:10.1371/journal.ppat.1012429
NLM
Xie SC, Guido RVC. A potent and selective reaction hijacking inhibitor of Plasmodium falciparum tyrosine tRNA synthetase exhibits single dose oral efficacy in vivo [Internet]. PLOS Pathogens. 2024 ; 20( 12): e1012429-1-e1012429-28 + supporting information.[citado 2025 out. 08 ] Available from: https://doi.org/10.1371/journal.ppat.1012429
Vancouver
Xie SC, Guido RVC. A potent and selective reaction hijacking inhibitor of Plasmodium falciparum tyrosine tRNA synthetase exhibits single dose oral efficacy in vivo [Internet]. PLOS Pathogens. 2024 ; 20( 12): e1012429-1-e1012429-28 + supporting information.[citado 2025 out. 08 ] Available from: https://doi.org/10.1371/journal.ppat.1012429
Artigo de periodico
Design of proteasome inhibitors with oral efficacy in vivo against Plasmodium falciparum and selectivity over the human proteasome (2021)
Xie, Stanley C. ; Aguiar, Anna Caroline Campos ; Guido, Rafael Victorio Carvalho
Fonte: Proceedings of the National Academy of Sciences of the United States of America - PNAS. Unidade: IFSC
Assuntos: PLASMODIUM FALCIPARUM, PLANEJAMENTO DE FÁRMACOS, MALÁRIA, QUÍMICA MÉDICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
XIE, Stanley C. e AGUIAR, Anna Caroline Campos e GUIDO, Rafael Victorio Carvalho. Design of proteasome inhibitors with oral efficacy in vivo against Plasmodium falciparum and selectivity over the human proteasome. Proceedings of the National Academy of Sciences of the United States of America - PNAS, v. 118, n. 39, p. e2107213118-1-e2107213118-9, 2021Tradução . . Disponível em: https://doi.org/10.1073/pnas.2107213118. Acesso em: 08 out. 2025.
APA
Xie, S. C., Aguiar, A. C. C., & Guido, R. V. C. (2021). Design of proteasome inhibitors with oral efficacy in vivo against Plasmodium falciparum and selectivity over the human proteasome. Proceedings of the National Academy of Sciences of the United States of America - PNAS, 118( 39), e2107213118-1-e2107213118-9. doi:10.1073/pnas.2107213118
NLM
Xie SC, Aguiar ACC, Guido RVC. Design of proteasome inhibitors with oral efficacy in vivo against Plasmodium falciparum and selectivity over the human proteasome [Internet]. Proceedings of the National Academy of Sciences of the United States of America - PNAS. 2021 ; 118( 39): e2107213118-1-e2107213118-9.[citado 2025 out. 08 ] Available from: https://doi.org/10.1073/pnas.2107213118
Vancouver
Xie SC, Aguiar ACC, Guido RVC. Design of proteasome inhibitors with oral efficacy in vivo against Plasmodium falciparum and selectivity over the human proteasome [Internet]. Proceedings of the National Academy of Sciences of the United States of America - PNAS. 2021 ; 118( 39): e2107213118-1-e2107213118-9.[citado 2025 out. 08 ] Available from: https://doi.org/10.1073/pnas.2107213118

Biblioteca Digital de Produção Intelectual da Universidade de São Paulo 2012 - 2025